SGCB and diabetes mellitus: Treatment with the sGC compounds Bay 41 or Bay 60 tended to prevent the diabetes-driven myelopoesis at the earlier time point (10-weeks after commencement of treatment), although this did not fall within statistical significance (Figures 4A,C,E; P = 0.2 between diabetic vehicle vs. diabetic + Bay41 (10 mg/kg) and diabetic + Bay60 (3 mg/kg)).